**Research Article**

**Title** [insert FULL TITLE here; no abbreviations]

[full NAMES (including first and middle names or initials) and AFFILIATIONS of all authors; no academic degrees]

**Running title:** [60 characters (including spaces) or less]

**Keywords:** [insert five descriptive keywords here]

**Financial support:** [including source and number of grants]

**Corresponding author:** [name, postal address, telephone and fax numbers, and email address]

**Conflicts of interest:** [insert any conflicts of interest here; otherwise ‘The authors declare no conflicts of interest]

**Word count:** [insert WORD COUNT here (excluding references); maximum 5000-6000 words of text]

**Total number of figures and tables:** [insert here; maximum 7 tables and/or figures]

**Abstract**

[insert ABSTRACT here; maximum 250 words; no references and minimal use of abbreviations, must include statement of implication (a single sentence that distills the overall findings and/or conclusions into a larger context for a general scientific audience]

**Introduction**

[insert TEXT here; a good introduction will be about one page of text, clearly state the problem, introduce relevant literature, note any controversies, and present the aim or hypothesis in the last paragraph; example reference format using Endnote: (1-4)]

**Materials and Methods**

[reference original texts when using established methods]

**Results**

[insert here; do not combine with DISCUSSION]

**Discussion**

[insert DISCUSSION here, must not be redundant with results section, highlight main conclusions in final paragraph]

**Acknowledgments**

[others who contributed to the work but are not listed as authors; seek written permission for those included here]

**References**

[maximum 50 references; we recommend using citation management software, such as Endnote; for an excellent free alternative see [Mendeley](http://www.mendeley.com/)]

1. Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, et al. Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer research. 2014;74:374-86.

2. Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, et al. Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:736-43.

3. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer discovery. 2013;3:182-97.

4. Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Molecular cancer research : MCR. 2013;11:1112-21.

**Tables**

[each on separate page, portrait, one-line title in bold, symbols and abbreviations immediately below the table with lower-case alphabetical letters; each table must have a descriptive title; include appropriate statistical analyses within tables]

**Figure Legends**

**Figure x.** [listed one after another; do not add legend to figure files; do not embed figures in this file; present each figure with a short summary of abut 15 words followed by a more comprehensive description]

[Did you find this template useful? To find out more about how Nextgenediting can help you publish visit <http://www.nextgenediting.com>. Connect with us via social media ([LinkedIn](http://www.linkedin.com/company/nextgenediting/), [Facebook](https://www.facebook.com/pages/Nextgenediting/131606863661962), or [Twitter](https://twitter.com/nextgenediting)) for news and special offers!]